MX2023011596A - Fosfolipidos como agentes quelantes de aniones en formulaciones farmaceuticas. - Google Patents
Fosfolipidos como agentes quelantes de aniones en formulaciones farmaceuticas.Info
- Publication number
- MX2023011596A MX2023011596A MX2023011596A MX2023011596A MX2023011596A MX 2023011596 A MX2023011596 A MX 2023011596A MX 2023011596 A MX2023011596 A MX 2023011596A MX 2023011596 A MX2023011596 A MX 2023011596A MX 2023011596 A MX2023011596 A MX 2023011596A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage forms
- phospholipids
- chelating agents
- pharmaceutical formulations
- methods
- Prior art date
Links
- 239000002738 chelating agent Substances 0.000 title abstract 3
- 150000001450 anions Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003904 phospholipids Chemical class 0.000 title 1
- 239000002552 dosage form Substances 0.000 abstract 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 125000000129 anionic group Chemical group 0.000 abstract 2
- 150000002500 ions Chemical class 0.000 abstract 2
- 229940067606 lecithin Drugs 0.000 abstract 2
- 235000010445 lecithin Nutrition 0.000 abstract 2
- 239000000787 lecithin Substances 0.000 abstract 2
- 150000003839 salts Chemical group 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se divulgan en el presente documento formas farmacéuticas que incluyen un material de relleno que incorpora un agente quelante aniónico, tal como lecitina, y una forma de sal de un principio activo farmacéutico básico o ácido y un ion libre. La relación molar entre el agente quelante aniónico, tal como lecitina, y el ion libre varía de aproximadamente 0,5 a aproximadamente 3. También se divulga en el presente documento métodos para estabilizar formas farmacéuticas que incluyen una forma de sal de un principio activo farmacéutico básico o ácido, métodos para preparar tales formas farmacéuticas, y métodos para usar tales formas farmacéuticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169330P | 2021-04-01 | 2021-04-01 | |
| PCT/US2022/022737 WO2022212639A1 (en) | 2021-04-01 | 2022-03-31 | Phospholipids as anion chelating agents in pharmaceutical formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011596A true MX2023011596A (es) | 2023-10-10 |
Family
ID=83459787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011596A MX2023011596A (es) | 2021-04-01 | 2022-03-31 | Fosfolipidos como agentes quelantes de aniones en formulaciones farmaceuticas. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240189241A1 (es) |
| EP (1) | EP4312941A4 (es) |
| JP (1) | JP2024512659A (es) |
| KR (1) | KR20230165280A (es) |
| CN (1) | CN117320678A (es) |
| AR (1) | AR125095A1 (es) |
| AU (1) | AU2022249084A1 (es) |
| BR (1) | BR112023019781A2 (es) |
| CA (1) | CA3213461A1 (es) |
| CO (1) | CO2023012992A2 (es) |
| IL (1) | IL307253A (es) |
| MX (1) | MX2023011596A (es) |
| WO (1) | WO2022212639A1 (es) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2879161A (en) * | 1956-05-14 | 1959-03-24 | American Cyanamid Co | Stable dry powder compositions containing choline chloride and methods of preparing same |
| US4612194A (en) * | 1984-02-15 | 1986-09-16 | Roshdy Ismail | Anti-rheumatic agents and their use |
| US4588717A (en) * | 1984-06-13 | 1986-05-13 | David C. Mitchell Medical Research Institute | Compounds and vitamin supplements and methods for making same |
| JP3157531B2 (ja) * | 1991-03-08 | 2001-04-16 | 昭和産業株式会社 | 血中コレステロール低下剤 |
| US5798392C1 (en) * | 1996-08-28 | 2002-06-04 | Univ Texas | Sulfonyl fluorides for the treatment of alzheimer's disease |
| GB9702799D0 (en) * | 1997-02-12 | 1997-04-02 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms |
| CN1615846A (zh) * | 2004-09-10 | 2005-05-18 | 李�杰 | 含有岩白菜素的软胶囊剂及其制备方法 |
| US8231896B2 (en) * | 2004-11-08 | 2012-07-31 | R.P. Scherer Technologies, Llc | Non-gelatin soft capsule system |
| CA2677253C (en) * | 2007-02-01 | 2015-06-30 | National Research Council Of Canada | Formulations of lipophilic bioactive molecules |
| JP4958054B2 (ja) * | 2009-01-23 | 2012-06-20 | 株式会社三協 | 粉末油脂配合咀嚼用ソフトカプセル |
| JP5800485B2 (ja) * | 2009-10-02 | 2015-10-28 | ロート製薬株式会社 | 鼻汁分泌抑制用組成物 |
| US10420729B2 (en) * | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
| CN106573077B (zh) * | 2014-06-30 | 2019-07-30 | 塔弗达治疗有限公司 | 靶向缀合物及其颗粒和制剂 |
| JP7065562B2 (ja) * | 2015-09-04 | 2022-05-12 | ロート製薬株式会社 | 医薬組成物 |
| JP2018065775A (ja) * | 2016-10-21 | 2018-04-26 | 東洋カプセル株式会社 | ナルフラフィン塩酸塩を含有するカプセル充填用組成物、軟カプセル剤及びその製造方法 |
| ES2995536T3 (en) * | 2017-07-12 | 2025-02-10 | Nutricia Nv | Method for treating traumatic brain injury |
| JP7459458B2 (ja) * | 2018-06-28 | 2024-04-02 | ライオン株式会社 | 内服組成物及びその製造方法 |
| WO2020051585A1 (en) * | 2018-09-07 | 2020-03-12 | R.P. Scherer Technologies, Llc | Solid or semisolid lipid based dosage form stabilization through curing and addition of low hlb surfactant(s) |
| CN113473974A (zh) * | 2019-01-25 | 2021-10-01 | 深圳市药欣生物科技有限公司 | 药物组合物 |
| US20220354800A1 (en) * | 2019-06-03 | 2022-11-10 | R.P. Scherer Technologies, Llc | Delayed release softgel capsules |
-
2022
- 2022-03-31 IL IL307253A patent/IL307253A/en unknown
- 2022-03-31 CA CA3213461A patent/CA3213461A1/en active Pending
- 2022-03-31 AU AU2022249084A patent/AU2022249084A1/en active Pending
- 2022-03-31 MX MX2023011596A patent/MX2023011596A/es unknown
- 2022-03-31 US US18/284,916 patent/US20240189241A1/en active Pending
- 2022-03-31 WO PCT/US2022/022737 patent/WO2022212639A1/en not_active Ceased
- 2022-03-31 CN CN202280026336.8A patent/CN117320678A/zh active Pending
- 2022-03-31 BR BR112023019781A patent/BR112023019781A2/pt unknown
- 2022-03-31 KR KR1020237037164A patent/KR20230165280A/ko active Pending
- 2022-03-31 EP EP22782170.9A patent/EP4312941A4/en active Pending
- 2022-03-31 JP JP2023560274A patent/JP2024512659A/ja active Pending
- 2022-04-01 AR ARP220100818A patent/AR125095A1/es unknown
-
2023
- 2023-09-29 CO CONC2023/0012992A patent/CO2023012992A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3213461A1 (en) | 2022-10-06 |
| US20240189241A1 (en) | 2024-06-13 |
| EP4312941A1 (en) | 2024-02-07 |
| AR125095A1 (es) | 2023-06-07 |
| EP4312941A4 (en) | 2025-02-26 |
| AU2022249084A1 (en) | 2023-11-09 |
| CN117320678A (zh) | 2023-12-29 |
| CO2023012992A2 (es) | 2023-10-30 |
| BR112023019781A2 (pt) | 2023-11-07 |
| WO2022212639A1 (en) | 2022-10-06 |
| IL307253A (en) | 2023-11-01 |
| JP2024512659A (ja) | 2024-03-19 |
| KR20230165280A (ko) | 2023-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007720A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
| PH12020550341A1 (en) | Niraparib formulations | |
| ES2091441T3 (es) | Composicion farmaceutica. | |
| AP1760A (en) | Platinum derivative pharmaceutical formulations. | |
| AR063471A1 (es) | Formulaciones para administracion parenteral de compuestos y sus usos | |
| MXPA05002814A (es) | Formulacion para agentes lipofilicos. | |
| EP1145719A3 (en) | Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| MX2022003570A (es) | Composiciones de vesícula extracelular. | |
| PH12021552020A1 (en) | Pharmaceutical formulations | |
| NZ752894A (en) | Formulations for administration of eflornithine | |
| MX2023011203A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
| MX418886B (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo | |
| TN2022000113A1 (en) | Dosing regimen for anti-dll3 agents | |
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| PH12022550441A1 (en) | Azaheteroaryl compound and application thereof | |
| MX2023011596A (es) | Fosfolipidos como agentes quelantes de aniones en formulaciones farmaceuticas. | |
| MX2021013488A (es) | Formulaciones liquidas de dosis oral de metilnaltrexona. | |
| MX2021004551A (es) | Composicion farmaceutica para el tratamiento de la anemia aplasica. | |
| BRPI0517574A (pt) | formulação farmacêutica, método para tratar ou prevenir hipercalcemia e método para preparar formulação farmacêutica | |
| WO2021151442A3 (en) | Methotrexate dosage form | |
| ZA202003904B (en) | Drug delivery system | |
| MY201954A (en) | Pharmaceutical composition comprising nebivolol with improved dissolution rate | |
| MX2018014407A (es) | Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando. | |
| JP6704702B2 (ja) | ヨウ素系殺菌成分を含有する水性外用組成物 |